Developer docs
API playgroundTry for free, no card

Search company profiles

Enzymatica

Full company profile

uuid0003zfa

Namestring
Enzymatica
Legal namestring
Enzymatica AB (publ)
Websiteurl
enzymatica.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Enzymatica AB (publ) is a Swedish life science company founded in 2007 and listed on Nasdaq First North Growth Market under the ticker ENZY, headquartered at Ideon Science Park in Lund with enzyme manufacturing at a wholly-owned facility in Reykjavik, Iceland. The company develops and commercializes ColdZyme Mouth Spray, a Class III medical device under EU MDR that forms a protective moisture barrier in the oral cavity and throat to inactivate viruses and inhibit their spread. The core technology is a patented enzyme from deep-sea cod, combined with plant-based glycerol, acquired through the 2016 purchase of Icelandic firm Zymetech and protected by composition-of-matter patents in the EU (until 2035), USA, Japan, China, and Australia (until 2036). Independent clinical studies published in The Journal of Physiology report ColdZyme reduces virus quantity by over 99% and shortens cold duration by approximately 50% versus placebo.

The business operates a hybrid model. Direct-to-consumer sales run through pharmacy chains in Sweden and select markets (UK via Amazon and Lloyds Pharmacy, plus ~20 additional countries via local distributors), while international growth increasingly relies on channel partners - notably STADA, which markets ColdZyme across Germany, Austria, Denmark, Norway, and Finland, and is set to drive the DACH launch from the 2026-2027 cold/flu season. Enzyme formulation licensing to local finished-product producers is positioned as the next margin lever. Beyond ColdZyme, the company markets a Barrier Technology Platform and pursues elite-sport validation partnerships (UK Sports Institute, GB Snowsport, Swedish Biathlon Federation, Aquatics GB, Unibet Rose Rockets cycling team) to anchor credibility. FY2025 net sales were SEK 53.9 million, up 18.3% YoY, against an operating loss of SEK -51.4 million and operating cash outflow of SEK -41.0 million, funded historically through recurring rights issues including SEK 132 million raised in September 2024. A leadership transition saw Sana Alajmovic appointed CEO in February 2026 and Holger Lembrér appointed CFO in April 2026, both tasked with driving international scale-up.

Short descriptiontext

Enzymatica AB is a Swedish life science company that develops and sells ColdZyme Mouth Spray, an EU MDR Class III medical device using a patented deep-sea cod enzyme to form a protective barrier against cold and flu viruses, sold through pharmacies and channel partners across roughly 20 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cold sore treatment, medical device mouth spray, upper respiratory infection, enzyme barrier technology, OTC cold remedy
Industry1 code
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
OTC Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1ColdZyme Product Sales
TypeOne Time License
Description

Sales of ColdZyme mouth spray consumer products through pharmacies, health stores, and e-commerce platforms in Sweden, UK, and other markets. Revenue grew 18.3% in 2025 to SEK 53.9 million.

news.cision.com
2Enzyme Formulation Licensing
TypeLicensing Royalties
Description

Enzymatica is transitioning to become a supplier of enzyme formulations to partners who produce finished products locally. This model offers higher EBIT margins while maintaining control over core technology through patents.

enzymatica.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Marketing or Sales, Technology or R&D, Supply Chain, Personnel, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ColdZyme
Description

Main product brand - a mouth spray that protects against viruses in the upper respiratory tract causing colds and flu-like symptoms. Forms a protective moisture barrier on the mucous membrane in the oral cavity and throat, inactivating viruses and inhibiting their ability to spread and multiply.

enzymatica.com
+3 more records
Core offering1 text field

Enzymatica develops and sells ColdZyme Mouth Spray, a Class III medical device that creates a protective moisture barrier in the oral cavity and throat to inactivate cold and flu viruses. The product is based on a proprietary enzyme formulation derived from deep-sea cod (trypsin) combined with plant-based glycerol, addressing the root cause of upper respiratory infections rather than only symptoms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Reduces cold duration by approximately 50% compared to placebo in elite athletes
+4 more records
Product overview1 text field

Enzymatica is a Lund-headquartered Swedish biotech company that develops solutions supporting the body's own defenses against virus, irritants and microorganisms. The company offers a unified product portfolio centered on ColdZyme Mouth Spray—a medical device that forms a protective barrier against cold and flu viruses. The core ColdZyme product is supported by Enzymatica's Barrier Technology Platform, which houses the proprietary enzyme formulation. The company has expanded the product line with new flavor variants including Eucalyptus (launched October 2025) and previously Strawberry. ColdZyme is classified as a Class III medical device under EU MDR regulations and is distributed through pharmacy and health retail channels, with strategic partnerships for international expansion including STADA for Germany and Austria.

Product and service2 records
1ColdZyme Mouth Spray
CategoryMedical Device / OTC Cold Remedy
Description

A medical device mouth spray that creates a protective moisture barrier on the mucosa of the mouth and throat to inactivate viruses (including cold, flu, and Omicron variants) and inhibit their ability to spread and multiply. ColdZyme addresses the root cause of colds and is sold through pharmacies, health stores, and e-commerce platforms for individual consumers.

2ColdZyme Eucalyptus Flavor
CategoryMedical Device / OTC Cold Remedy
Description

An alternative eucalyptus-flavored variant of the ColdZyme Mouth Spray medical device offering the same protective enzymatic barrier against upper respiratory viruses. Launched in Sweden in October 2025.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-08
Description

Enzymatica partnered with the Unibet Rose Rockets cycling team to include ColdZyme in the Giro d'Italia race routine.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-31
Description

Enzymatica and STADA signed a partnership agreement to launch and distribute ColdZyme in Germany and Austria. The collaboration combines Enzymatica's medical device with STADA's commercial platform, focusing on marketing ColdZyme under STADA's brands. Full commercial impact anticipated from 2026-2027 cold and flu season, with progressive realization expected from 2027.

3UK Sports Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-20
Description

ColdZyme has entered a partnership with the UK Sports Institute to support athlete health and performance, supplying ColdZyme for UKSI's athlete health initiatives. The collaboration aims to reduce illness-related disruptions among Olympic and Paralympic athletes during training and competitions. This initiative is expected to be sustained over multiple years.

news.cision.com
4Swedish Biathlon Federation
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Enzymatica became official supplier to the Swedish Biathlon Federation, providing ColdZyme for athlete health support.

prnewswire.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-21
Description

Enzymatica announced partnership with GB Snowsport to strengthen presence in elite winter sports and support British athletes.

6Aquatics GB
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-19
Description

Partnership with UK Sports Institute/Aquatics GB to supply ColdZyme for athlete protection during training and competitions.

enzymatica.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

In 2016, Enzymatica acquired the Icelandic company Zymetech, gaining exclusive global rights to the patented enzyme from deep-sea cod. The acquisition gave Enzymatica control over enzyme manufacturing, access to international R&D expertise, and Zymetech's research portfolio.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Betadine (Mundipharma)
TypeDirect peer
Description

Povidone-iodine based antiseptic brand including throat spray for sore throats and infections. Comparable as a throat spray medical device positioned in the same cold/sore throat category with similar pharmacy distribution.

TypeBroad incumbent
Description

Major European consumer health and generics company that is Enzymatica's distribution partner for Germany, Austria, Denmark, Norway, and Finland. Comparable as a leading OTC and consumer healthcare platform across Europe with broad respiratory/cold product portfolio.

TypeDirect peer
Description

Iconic OTC cold/cough brand (Vicks VapoRub, NyQuil, DayQuil) with global distribution. Comparable as a direct competitor in the consumer cold remedy category where Enzymatica competes for pharmacy shelf space and consumer share of throat/nasal care.

TypeEmerging player
Description

Biotech that licenses its proprietary enzyme-based drug delivery platform (ENHANZE) to multiple partners. Comparable as a business-model peer pursuing an enzyme-platform licensing strategy in healthcare, mirroring Enzymatica's planned transition to enzyme formulation licensing.

TypeDirect peer
Description

Zinc-based cold remedy lozenges/sprays marketed for cold duration reduction. Comparable as a directly competitive mechanism-based OTC cold remedy targeting similar efficacy claims.

6Strepsils (Reckitt Benckiser)
TypeDirect peer
Description

Leading global throat lozenge/spray brand for sore throats and colds. Comparable as direct competitor in OTC throat and cold symptom relief sold through the same pharmacy channels.

TypeBroad incumbent
Description

Global consumer health leader with major respiratory brands (Throaties, Coldrex, Otrivin nasal). Comparable as a broad incumbent with deep OTC respiratory/throat franchise and pharmacy relationships.

TypeBroad incumbent
Description

Global consumer health giant (Strepsils, Nurofen, Mucinex, Durex) with extensive OTC respiratory portfolio. Comparable as a broad incumbent competing across Enzymatica's category with substantially larger marketing and distribution resources.

TypeDirect peer
Description

OTC cold remedy brand built on zinc-based mechanism, sold as nasal swabs and oral products. Comparable as a mechanism-driven cold remedy (similar to ColdZyme's barrier approach) competing for the same 'root cause' positioning in cold care.

TypeBroad incumbent
Description

Global consumer health company already distributing ColdZyme under Aderogyl and Bisolviral brands in Mexico and Turkey. Comparable as a broad OTC player with overlapping respiratory/cold portfolio and distribution scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Enzymatica

OTC Medical Devicesenzymatica.com

Enzymatica AB is a Swedish life science company that develops and sells ColdZyme Mouth Spray, an EU MDR Class III medical device using a patented deep-sea cod enzyme to form a protective barrier against cold and flu viruses, sold through pharmacies and channel partners across roughly 20 countries.

What Enzymatica does

Enzymatica AB (publ) is a Swedish life science company founded in 2007 and listed on Nasdaq First North Growth Market under the ticker ENZY, headquartered at Ideon Science Park in Lund with enzyme manufacturing at a wholly-owned facility in Reykjavik, Iceland. The company develops and commercializes ColdZyme Mouth Spray, a Class III medical device under EU MDR that forms a protective moisture barrier in the oral cavity and throat to inactivate viruses and inhibit their spread. The core technology is a patented enzyme from deep-sea cod, combined with plant-based glycerol, acquired through the 2016 purchase of Icelandic firm Zymetech and protected by composition-of-matter patents in the EU (until 2035), USA, Japan, China, and Australia (until 2036). Independent clinical studies published in The Journal of Physiology report ColdZyme reduces virus quantity by over 99% and shortens cold duration by approximately 50% versus placebo.

The business operates a hybrid model. Direct-to-consumer sales run through pharmacy chains in Sweden and select markets (UK via Amazon and Lloyds Pharmacy, plus ~20 additional countries via local distributors), while international growth increasingly relies on channel partners - notably STADA, which markets ColdZyme across Germany, Austria, Denmark, Norway, and Finland, and is set to drive the DACH launch from the 2026-2027 cold/flu season. Enzyme formulation licensing to local finished-product producers is positioned as the next margin lever. Beyond ColdZyme, the company markets a Barrier Technology Platform and pursues elite-sport validation partnerships (UK Sports Institute, GB Snowsport, Swedish Biathlon Federation, Aquatics GB, Unibet Rose Rockets cycling team) to anchor credibility. FY2025 net sales were SEK 53.9 million, up 18.3% YoY, against an operating loss of SEK -51.4 million and operating cash outflow of SEK -41.0 million, funded historically through recurring rights issues including SEK 132 million raised in September 2024. A leadership transition saw Sana Alajmovic appointed CEO in February 2026 and Holger Lembrér appointed CFO in April 2026, both tasked with driving international scale-up.

Enzymatica firmographics

Firmographics
Name
Enzymatica
Legal name
Enzymatica AB (publ)
Website
https://enzymatica.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Enzymatica AB is a Swedish life science company that develops and sells ColdZyme Mouth Spray, an EU MDR Class III medical device using a patented deep-sea cod enzyme to form a protective barrier against cold and flu viruses, sold through pharmacies and channel partners across roughly 20 countries.
Ownership category
akta.pro rank

Enzymatica industry classification

Industry
Product category
OTC Medical Devices
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Cold sore treatment
  • Medical device mouth spray
  • Upper respiratory infection
  • Enzyme barrier technology
  • OTC cold remedy

Where Enzymatica is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices2 records

Markets served

Enzymatica business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Technology or R&D, Supply Chain, Personnel, Operations

Revenue model

  1. ColdZyme Product Sales: Sales of ColdZyme mouth spray consumer products through pharmacies, health stores, and e-commerce platforms in Sweden, UK, and other markets. Revenue grew 18.3% in 2025 to SEK 53.9 million.
  2. Enzyme Formulation Licensing: Enzymatica is transitioning to become a supplier of enzyme formulations to partners who produce finished products locally. This model offers higher EBIT margins while maintaining control over core technology through patents.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Enzymatica product offering

Product offering

Core offering

Enzymatica develops and sells ColdZyme Mouth Spray, a Class III medical device that creates a protective moisture barrier in the oral cavity and throat to inactivate cold and flu viruses. The product is based on a proprietary enzyme formulation derived from deep-sea cod (trypsin) combined with plant-based glycerol, addressing the root cause of upper respiratory infections rather than only symptoms.

Product overview

Enzymatica is a Lund-headquartered Swedish biotech company that develops solutions supporting the body's own defenses against virus, irritants and microorganisms. The company offers a unified product portfolio centered on ColdZyme Mouth Spray—a medical device that forms a protective barrier against cold and flu viruses. The core ColdZyme product is supported by Enzymatica's Barrier Technology Platform, which houses the proprietary enzyme formulation. The company has expanded the product line with new flavor variants including Eucalyptus (launched October 2025) and previously Strawberry. ColdZyme is classified as a Class III medical device under EU MDR regulations and is distributed through pharmacy and health retail channels, with strategic partnerships for international expansion including STADA for Germany and Austria.

Differentiator

Problem solved

Functional benefit

Brands

  • ColdZyme: Main product brand - a mouth spray that protects against viruses in the upper respiratory tract causing colds and flu-like symptoms. Forms a protective moisture barrier on the mucous membrane in the oral cavity and throat, inactivating viruses and inhibiting their ability to spread and multiply.
  • ColdZyme Mouth Spray
  • ColdZyme Eucalyptus
  • ColdZyme One Cold

Products and services

  • ColdZyme Mouth Spray A medical device mouth spray that creates a protective moisture barrier on the mucosa of the mouth and throat to inactivate viruses (including cold, flu, and Omicron variants) and inhibit their ability to spread and multiply. ColdZyme addresses the root cause of colds and is sold through pharmacies, health stores, and e-commerce platforms for individual consumers.
  • ColdZyme Eucalyptus Flavor An alternative eucalyptus-flavored variant of the ColdZyme Mouth Spray medical device offering the same protective enzymatic barrier against upper respiratory viruses. Launched in Sweden in October 2025.

Quantifiable outcome

  • Reduces cold duration by approximately 50% compared to placebo in elite athletes
  • +4 more outcomes

Companies that use Enzymatica

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Enzymatica technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Enzymatica partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Unibet Rose Rockets (Team d'Amico)minorGTM or Marketing Partner · 8 June 2026Enzymatica partnered with the Unibet Rose Rockets cycling team to include ColdZyme in the Giro d'Italia race routine.
  • STADAcoreChannel Partner/ Reseller/ Distributor · 31 March 2026Enzymatica and STADA signed a partnership agreement to launch and distribute ColdZyme in Germany and Austria. The collaboration combines Enzymatica's medical device with STADA's commercial platform, focusing on marketing ColdZyme under STADA's brands. Full commercial impact anticipated from 2026-2027 cold and flu season, with progressive realization expected from 2027.
  • UK Sports InstitutecoreStrategic or Co-development Partner · 20 November 2025ColdZyme has entered a partnership with the UK Sports Institute to support athlete health and performance, supplying ColdZyme for UKSI's athlete health initiatives. The collaboration aims to reduce illness-related disruptions among Olympic and Paralympic athletes during training and competitions. This initiative is expected to be sustained over multiple years.
  • Swedish Biathlon FederationminorStrategic or Co-development Partner · 30 October 2025Enzymatica became official supplier to the Swedish Biathlon Federation, providing ColdZyme for athlete health support.
  • GB SnowsportminorStrategic or Co-development Partner · 21 October 2025Enzymatica announced partnership with GB Snowsport to strengthen presence in elite winter sports and support British athletes.
  • Aquatics GBminorStrategic or Co-development Partner · 19 June 2025Partnership with UK Sports Institute/Aquatics GB to supply ColdZyme for athlete protection during training and competitions.
  • ZymetechcoreOEM/ Whitelabel/ Licensing PartnerIn 2016, Enzymatica acquired the Icelandic company Zymetech, gaining exclusive global rights to the patented enzyme from deep-sea cod. The acquisition gave Enzymatica control over enzyme manufacturing, access to international R&D expertise, and Zymetech's research portfolio.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Enzymatica competitors and assessment

Company assessment

Direct peers

  • Betadine (Mundipharma): Povidone-iodine based antiseptic brand including throat spray for sore throats and infections. Comparable as a throat spray medical device positioned in the same cold/sore throat category with similar pharmacy distribution.
  • Vicks (Procter & Gamble): Iconic OTC cold/cough brand (Vicks VapoRub, NyQuil, DayQuil) with global distribution. Comparable as a direct competitor in the consumer cold remedy category where Enzymatica competes for pharmacy shelf space and consumer share of throat/nasal care.
  • Cold-EEZE (ProPhase Labs): Zinc-based cold remedy lozenges/sprays marketed for cold duration reduction. Comparable as a directly competitive mechanism-based OTC cold remedy targeting similar efficacy claims.
  • Strepsils (Reckitt Benckiser): Leading global throat lozenge/spray brand for sore throats and colds. Comparable as direct competitor in OTC throat and cold symptom relief sold through the same pharmacy channels.
  • Zicam (Church & Dwight / Matrixx Initiatives): OTC cold remedy brand built on zinc-based mechanism, sold as nasal swabs and oral products. Comparable as a mechanism-driven cold remedy (similar to ColdZyme's barrier approach) competing for the same 'root cause' positioning in cold care.

Broad incumbents

  • STADA Arzneimittel AG: Major European consumer health and generics company that is Enzymatica's distribution partner for Germany, Austria, Denmark, Norway, and Finland. Comparable as a leading OTC and consumer healthcare platform across Europe with broad respiratory/cold product portfolio.
  • GSK Consumer Healthcare: Global consumer health leader with major respiratory brands (Throaties, Coldrex, Otrivin nasal). Comparable as a broad incumbent with deep OTC respiratory/throat franchise and pharmacy relationships.
  • Reckitt Benckiser: Global consumer health giant (Strepsils, Nurofen, Mucinex, Durex) with extensive OTC respiratory portfolio. Comparable as a broad incumbent competing across Enzymatica's category with substantially larger marketing and distribution resources.
  • Sanofi Consumer Healthcare: Global consumer health company already distributing ColdZyme under Aderogyl and Bisolviral brands in Mexico and Turkey. Comparable as a broad OTC player with overlapping respiratory/cold portfolio and distribution scale.

Emerging players

  • Halozyme Therapeutics: Biotech that licenses its proprietary enzyme-based drug delivery platform (ENHANZE) to multiple partners. Comparable as a business-model peer pursuing an enzyme-platform licensing strategy in healthcare, mirroring Enzymatica's planned transition to enzyme formulation licensing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Enzymatica social profiles

Digital presence

Enzymatica compliance and trust

Trust signal

Compliance2 records

Enzymatica financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Enzymatica leadership team

Management profile

Number of profiles

Profiles4 records

Enzymatica subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Enzymatica funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Enzymatica M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enzymatica

What does Enzymatica do?

Enzymatica develops and sells ColdZyme Mouth Spray, a Class III medical device that creates a protective moisture barrier in the oral cavity and throat to inactivate cold and flu viruses. The product is based on a proprietary enzyme formulation derived from deep-sea cod (trypsin) combined with plant-based glycerol, addressing the root cause of upper respiratory infections rather than only symptoms.

Is Enzymatica a public or private company?

Enzymatica is a public company. It is classified as public and is currently operating.

When was Enzymatica founded?

Enzymatica was founded in 2007. It employs 11 to 50 people.

Where is Enzymatica based?

Enzymatica is headquartered in Lund, Sweden, in the Europe region.

How does Enzymatica make money?

Two revenue lines are on record. ColdZyme Product Sales are the primary driver. The others are enzyme Formulation Licensing.

Who are Enzymatica's main competitors?

Direct peers on record are Betadine (Mundipharma), Vicks (Procter & Gamble), Cold-EEZE (ProPhase Labs), Strepsils (Reckitt Benckiser) and Zicam (Church & Dwight / Matrixx Initiatives). Broad incumbents are STADA Arzneimittel AG, GSK Consumer Healthcare, Reckitt Benckiser and Sanofi Consumer Healthcare. Halozyme Therapeutics is listed as an emerging player.

Does Enzymatica have an API?

No public API is recorded for Enzymatica.

What industry is Enzymatica in?

Enzymatica's product category is OTC Medical Devices. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingEnzymatica Q3 operating loss narrows 53% year over year to SEK 3.9 millionEnzymatica's Q3 2026 operating loss narrowed 53% year over year to SEK 3.9 million, while net sales fell to SEK 14.57 million. UK net sales rose 51% to SEK 1.7 million, and operating expenses dropped 24% to SEK 13.33 million. First deliveries reached STADA in Germany, and a MedonyX partnership expanded ColdZyme's reach to Jordan and Iraq.The future of tradingEnzymatica Board Member Guðmundur Pálmason Steps Down for Personal ReasonsEnzymatica announced Guðmundur Pálmason's board departure for personal reasons on October 27, 2026, after serving since 2016. An August 27 announcement confirmed additions to group management, including a Nordic marketing and sales director and chief scientist.TradingViewEnzymatica AB (ENZY) Q3 Loss Narrows; Sales SEK 14.6MEnzymatica AB reported Q3 net sales of SEK 14.6M, down from SEK 15.0M, and an operating loss of SEK -3.9M, narrowing from SEK -8.2M. EPS was SEK -0.02, and cash flow from operations was SEK -5.8M. The company expects new channels, including MENA launches in 2027, to aid growth pending approvals.The future of tradingEnzymatica appoints Katja Margell as Director of Investor Relations & Corporate AffairsEnzymatica appointed Katja Margell as Director of Investor Relations & Corporate Affairs, effective 1 November 2026. She will oversee investor relations, corporate communications, public affairs, and stakeholder engagement, including raising awareness of Enzymatica and ColdZyme. The appointment supports the company's commercial and international ambitions.TradingViewEnzymatica appoints Katja Margell as Director of Investor Relations & Corporate AffairsEnzymatica appointed Katja Margell as Director of Investor Relations & Corporate Affairs, effective 1 November 2026. She will oversee investor relations, corporate communications, public affairs, and stakeholder relations, including policy and strategic engagement with medical opinion leaders and patient organizations. The role aims to raise awareness of Enzymatica and ColdZyme to support commercial and international ambitions.TradingViewEnzymatica AB (publ) (ENZY) Approves Up To 1,000,000 Warrants For LTIPEnzymatica AB shareholders approved a 2026/2029 warrant-based LTIP of up to 1,000,000 warrants, exercisable Oct–Dec 2029 at 200% of the VWAP set after Oct 28, 2026. Warrants will be transferred at market value to employees and key individuals, adding potential dilution overhang.TradingViewBulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 October 2026Enzymatica AB's shareholders approved a long-term incentive program on 22 October 2026, issuing up to 1,000,000 warrants. Each warrant gives one share at 200% of the volume-weighted average price, exercisable from 1 October to 31 December 2029.The future of tradingEnzymatica signs exclusive ColdZyme distribution deal with MedonyX for Jordan and IraqEnzymatica signed an exclusive ColdZyme distribution agreement with MedonyX for Jordan and Iraq on October 21, 2026. The deal targets a combined population of nearly 58 million and marks Enzymatica's first entry into the Middle East and North Africa. Launches in both countries are expected in the first quarter of 2027, subject to local regulatory approval.The future of tradingSTADA launches Virustad in Germany – based on Enzymatica's ColdZyme® technologySTADA launched the oral spray Virustad in Germany, built on Enzymatica's ColdZyme technology. The product forms a protective barrier against cold viruses and is supported by a 2025 study showing a 94% lower rhinovirus load. The launch builds on a March 2026 partnership, with full integration expected for the 2027 cold season.news.cision.comBulletin from annual general meeting of Enzymatica AB (publ) on 7 May 2026Enzymatica AB held its annual general meeting on 7 May 2026, adopting financial statements and resolutions. The meeting decided no dividend for 2025, re-elected five board members and Deloitte as auditor, and authorized a share capital increase up to 10% of shares.